As the second quarter showed the worst quarterly fall in output ever recorded in the UK, investors point to how the recovery of the UK economy as a whole may rely on the prosperity of SMEs, start-ups and high-growth firms.
InnovHeart, a developer of novel transcatheter mitral valve replacement systems for the treatment of mitral valve disease, has received EUR20 million in a round of equity financing from a syndicate of investors. The Series B round was raised from existing Milan-based investor Genextra which has been the sole investor since
Madrid-based Bnext, a provider of alternative banking services, has secured USD13 million (EUR11million) in another capital investment round by its existing investors. The startup’s total investments received to date are slightly above GBP43 million. In October 2019 DN Capital led its first investment round into the company, together with Redalpine
Karma Ventures and byFounders have led a USD6.1 million funding round in Icelandic anti-money laundering startup Lucinity. Existing investors Nordic based Crowberry Capital and US based early stage investor Preceptor Capital also participated in the founding round. The software startup Lucinity is an Anti-Money-Laundering app that “uses human AI to
Jan Pensaert is the founder and managing partner of Valiance, a global life sciences investor focused on addressing the unmet needs of a growing and ageing population. Valiance makes an impact through investments in medtech, with an additional focus on digital and nutritional health.
BGF’s total H1 investment stands at GBP177 million, including GBP128 million into new portfolio companies and GBP49 million into existing portfolio companies. BGF backed 24 new companies in the first half of 2020, while completing eight exits. Some of its latest deals include British ceramics manufacturing company Emma Bridgewater, Bayfield
PROfounders Capital and Calm/Storm Ventures have invested GBP1 million into sex therapy app Blueheart. The fresh capital will be used to expand the available suite of therapy sessions and advance therapeutic research, as well as improving the app’s AI capabilities. The app provides sex and relationship therapy based on
Eurazeo has completed a EUR80 million investment from its China Acceleration Fund in DORC (Dutch Ophthalmic Research Center), a specialist in the area of vitreoretinal surgery.
Advent France Biotechnology and Invivo Ventures have invested EUR4.25 million into Valencia-based Arthex Biotech, a pre-clinical stage life sciences company focused on the development of next generation antisense RNA therapies. The latest round follows on from an initial seed round of EUR2.7 million by Invivo and CDTI-Innvierte in December 2019,
Evolution Equity Partners has led a Series C round in Quantexa, a decision intelligence software company that enables organisations to make better decisions, raising a further USD64.7 million in funding.
12 November, 2026 – 5:00 pm
12 November, 2026 – 8:00 am
12 February, 2026 – 8:00 am
12 February, 2026 – 5:00 pm
